Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
It is not intended for human or veterinary use, clinical administration, diagnostic procedures, or any form of therapeutic use
If your vial has been exposed to temperatures above 30 degrees Celsius for more than a few hours, assume significant potency loss
These actions underscore active regulatory oversight
Let the liquid flow gently to dissolve the powder
Leqvio +114% cc Key Peptide Products: Lutathera (lutetium-177 DOTATATE, oncology peptide receptor radionuclide), Pluvicto (177Lu-PSMA-617), Sandostatin/Signifor (octreotide/pasireotide somatostatin analogues), Leqvio (inclisiran siRNA, category-adjacent) Therapeutic Segments: Oncology (radioligand therapy, CDK4/6 inhibitors)
Maintenance Phase: Monthly Injections After the loading phase, patients move to a maintenance phase
US$ 26.62
US$ 27.11
US$ 21.64
US$ 28.50
US$ 22.96
